A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-13

Study Completion Date

2024-09-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the effect of BGM0504 injection versus placebo on weight loss in overweight or obese subjects after 24 weeks of treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of BGM0504 Injection in Participants with Obesity or Overweight

NCT06704581

Overweight or Obesity

RECRUITING PHASE3

A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects

NCT07239973

Healthy Non-diabetic Overweight or Obese

RECRUITING PHASE1

A Study of BGM0504 in Participants With Obesity

NCT06911203

Obesity

RECRUITING PHASE2

A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants

NCT07294235

Overweight or Obesity

RECRUITING PHASE1

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects

NCT07166081

Non-diabetic Overweight or Obese

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overweight or Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

5 mg BGM0504

5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.

Group Type EXPERIMENTAL

BGM0504

Intervention Type DRUG

Administered SC

10 mg BGM0504

10 mg BGM0504 administered SC once a week.

Group Type EXPERIMENTAL

BGM0504

Intervention Type DRUG

Administered SC

15 mg BGM0504

15 mg BGM0504 administered SC once a week.

Group Type EXPERIMENTAL

BGM0504

Intervention Type DRUG

Administered SC

Placebo

Placebo administered SC once a week.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered SC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BGM0504

Administered SC

Intervention Type DRUG

BGM0504

Administered SC

Intervention Type DRUG

BGM0504

Administered SC

Intervention Type DRUG

Placebo

Administered SC

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. BMI ≥ 28.0 kg/m2 or 24.0 ≤ BMI \< 28.0 kg/m2 with at least 1 weight-related comorbidity at screening visit; 2.Controlled by diet and exercise alone for at least 12 weeks prior to Screening with \<5.0% change in body weight and able to continue the original diet and exercise for weight control during the trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No